Chapter 26. The Cannabinoids: Therapeutic Potentials
References (50)
- et al.
Prostaglandins
(1972) - et al.
Biochem. Pharmacol.
(1973) - et al.
Eur. J. Pharmacol.
(1973) - et al.
Life Sci.
(1973) - et al.
Experimental Neurology
(1973) - et al.
Eur. J. Pharmacol.
(1972) - et al.
Eur. J. Pharmacol.
(1973) - et al.
Eur. J. Pharmacol.
(1973) - et al.
Eur. J. Pharmacol.
(1973) - et al.
Neuropharmacology
(1973)
Life Sci.
Psychopharmacologia
Nature New Biol.
Res. Commun. Chem. Pathol. Pharmacol.
J. Pharmacol. Exp. Therapeutics
Nature
Toxicol. Appl. Pharmacol.
Psychopharmacologia
Epilepsia
Fed. Proc.
Pharmacol. Rev.
Psychopharmacologia
Br. J. Pharmacol.
Cited by (11)
Blood pressure regulation by endocannabinoids and their receptors
2005, NeuropharmacologyCitation Excerpt :The beneficial effects of cannabinoids could involve improvement of tissue oxygenation by counteracting the excessive sympathetic vasoconstriction triggered by hemorrhage or myocardial infarction and also potent anti-inflammatory effects (reviewed in Hiley and Ford, 2003, 2004; Walter and Stella, 2004). The intriguing possibility of using cannabinoid ligands as antihypertensive agents was first considered more than 30 years ago (Archer, 1974; Adams et al., 1977; Birmingham, 1973; Crawford and Merritt, 1979; Varma and Goldbaum, 1975; Zaugg and Kyncl, 1983). However, initial enthusiasm was tempered by the inability to separate the neurobehavioral and cardiovascular effects of cannabinergic ligands and also by a report of the development of rapid tolerance to the hypotensive and bradycardic effects of THC (Adams et al., 1976).
Endocannabinoid system in cardiovascular disorders-new pharmacotherapeutic opportunities
2011, Journal of Pharmacy and Bioallied SciencesTherapeutic potential of cannabinoids in the treatment of neuroinflammation associated with parkinson's disease
2011, Mini-Reviews in Medicinal ChemistryBlood pressure lowering effects of rimonabant in obesity-related hypertension
2008, Journal of NeuroendocrinologyCannabinoids as therapeutic agents in cardiovascular disease: A tale of passions and illusions
2007, British Journal of Pharmacology